share_log

Quoin Pharmaceuticals FY 2024 GAAP EPS $(1.91) Beats $(2.10) Estimate, Quoin Had Approximately $14.1M In Cash, Cash Equivalents And Marketable That Is Expected To Fund The Company's Operations Into Q2 Of 2026

Benzinga ·  Mar 13 11:37

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.10) by 9.05 percent.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 332

Recommended

Write a comment